Jae Y. Lee

Jae Y. Lee

Auto-generated profile, based on publicly available information

Jae Y. Lee

Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2010 in Blood
Verified
Journal Article
Closed access
PDF file
FLFei Liu
Fei Liu
JLJae Y. Lee
Jae Y. Lee
HWHuijun Wei
Huijun Wei
OTOsamu Tanabe
Osamu Tanabe
JEJames D. Engel
James D. Engel
JGJun-Lin Guan
Jun-Lin Guan
Little is known about whether autophagic mechanisms are active in hematopoietic stem cells (HSCs) or how they are regulated. FIP200 (200-kDa FAK-family interacting protein) plays important roles in mammalian autophagy and other cellular functions, but its role in hematopoietic cells has not been examined. Here we show that conditional deletion of FIP200 in hematopoietic cells leads to perinatal lethality and severe anemia. FIP200 was cell-autonomously required for the maintenance and function of fetal HSCs. FIP200-deficient HSC were unable to reconstitute lethally irradiated recipients. FIP200 ablation did not result in increased HSC apoptosis, but it did increase the rate of HSC proliferation. Consistent with an essential role for FIP200 in autophagy, FIP200-null fetal HSCs exhibited both increased mitochondrial mass and reactive oxygen species. These data identify FIP200 as a key intrinsic regulator of fetal HSCs and implicate a potential role for autophagy in the maintenance of fetal hematopoiesis and HSCs.

1 September 2012 in Cell Stem Cell
Verified
Journal Article
Closed access
JMJeffrey A. Magee
Jeffrey A. Magee
TITsuneo Ikenoue
Tsuneo Ikenoue
DNDaisuke Nakada
Daisuke Nakada
JLJae Y. Lee
Jae Y. Lee
KGKun-Liang Guan
Kun-Liang Guan
SMSean J. Morrison
Sean J. Morrison

1 November 2010 in Cell Stem Cell
Verified
Journal Article
Closed access
JLJae Y. Lee
Jae Y. Lee
DNDaisuke Nakada
Daisuke Nakada
OYOmer H. Yilmaz
Omer H. Yilmaz
ZTZuzana Tothova
Zuzana Tothova
NJNancy M. Joseph
Nancy M. Joseph
SMSean J. Morrison
Sean J. Morrison

1 January 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PHPeter G. Hawkins
Peter G. Hawkins
JLJae Y. Lee
Jae Y. Lee
YMYanping Mao
Yanping Mao
PLPin Li
Pin Li
MGMichael Green
Michael Green
Avraham EisbruchAvraham Eisbruch
Avraham Eisbruch

1 March 2017 in Journal of Urology
Verified
Journal Article
Closed access
AAAhmed Abugharib
Ahmed Abugharib
WJWilliam C. Jackson
William C. Jackson
VTVasu Tumati
Vasu Tumati
RDRobert T. Dess
Robert T. Dess
JLJae Y. Lee
Jae Y. Lee
DSDaniel Spratt
Daniel Spratt
Early salvage radiotherapy following radical prostatectomy for prostate cancer is commonly advocated in place of adjuvant radiotherapy. We aimed to determine the optimal definition of early salvage radiotherapy. We performed a multi-institutional retrospective study of 657 men who underwent salvage radiotherapy between 1986 and 2013. Two comparisons were made to determine the optimal definition of early salvage radiotherapy, including 1) the time from radical prostatectomy to salvage radiotherapy (less than 9, 9 to 21, 22 to 47 or greater than 48 months) and 2) the level of detectable pre-salvage radiotherapy prostate specific antigen (0.01 to 0.2, greater than 0.2 to 0.5 or greater than 0.5 ng/ml). Outcomes included freedom from salvage androgen deprivation therapy, and biochemical relapse-free, distant metastases-free and prostate cancer specific survival. Median followup was 9.8 years. Time from radical prostatectomy to salvage radiotherapy did not correlate with 10-year biochemical relapse-free survival rates (R2 = 0.18). Increasing pre-salvage radiotherapy prostate specific antigen strongly correlated with biochemical relapse-free survival (R2 = 0.91). Increasing detectable pre-salvage radiotherapy prostate specific antigen (0.01 to 0.2, greater than 0.2 to 0.5 and greater than 0.5 ng/ml) predicted worse 10-year biochemical relapse-free survival (62%, 44% and 27%), freedom from salvage androgen deprivation therapy (77%, 66% and 49%), distant metastases-free survival (86%, 79% and 66%, each p <0.001) and prostate cancer specific survival (93%, 89% and 80%, respectively, p = 0.001). On multivariable analysis early salvage radiotherapy (prostate specific antigen greater than 0.2 to 0.5 ng/ml) was associated with a twofold increase in biochemical failure, use of salvage androgen deprivation therapy and distant metastases compared to very early salvage radiotherapy (prostate specific antigen 0.01 to 0.2 ng/ml). The duration from radical prostatectomy to salvage radiotherapy is not independently prognostic for outcomes after salvage radiotherapy and it should not be used to define early salvage radiotherapy. Grouping all patients with pre-salvage radiotherapy prostate specific antigen 0.5 ng/ml or less may be inadequate to define early salvage radiotherapy and it has a relevant impact on ongoing and future clinical trials.

1 May 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
JLJae Y Lee
Jae Y Lee
DSDaniel E Spratt
Daniel E Spratt
ALAdam L Liss
Adam L Liss
PMPatrick W McLaughlin
Patrick W McLaughlin